Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 13:6:101705.
doi: 10.1016/j.jaccas.2022.101705. eCollection 2023 Jan 18.

Asymptomatic Apical Hypertrophic Cardiomyopathy in an Elite Competitive Athlete

Athena L Huang  1 , James MacNamara  1 , Mark S Link  1 , Matthew Martinez  2 , Joseph A Dearani  3 , Bryan C Cannon  3 , Benjamin D Levine  1 , Michael J Ackerman  3
Affiliations
Case Reports

Asymptomatic Apical Hypertrophic Cardiomyopathy in an Elite Competitive Athlete

Athena L Huang et al. JACC Case Rep. .

Abstract

A 17-year-old male elite athlete presented for evaluation after an abnormal pre-competitive college screening electrocardiogram. Subsequent evaluation revealed the presence of hypertrophic cardiomyopathy. He remained asymptomatic throughout four years of follow-up. Through shared decision making, he continued to play competitively and is now a professional athlete. (Level of Difficulty: Advanced.).

Keywords: CMR, cardiac magnetic resonance imaging; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; LVOT, left ventricular outflow tract; SCD, sudden cardiac death; SDM, shared decision making; TTE, transthoracic echocardiography; competitive athlete; hypertrophic cardiomyopathy; shared decision making.

PubMed Disclaimer

Conflict of interest statement

This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (to Dr Ackerman). Dr Ackerman is a consultant for Abbott, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Invitae, LQT Therapeutics, Medtronic, and UpToDate, and with the Mayo Clinic has equity, intellectual property, or royalty relationships with AliveCor, Anumana, ARMGO Pharma, and Pfizer, none of which were involved in this manuscript in any way. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
12-Lead Electrocardiogram Normal sinus rhythm, voltage criteria for left ventricular hypertrophy, and deep T-wave inversions in leads II, III, aVF, and V3-V6. Note normalization of T-wave in lead aVR, which is classic in apical hypertrophic cardiomyopathy.
Figure 2
Figure 2
Cardiac Magnetic Resonance Imaging (A and C) Initial CMR showed a maximum wall thickness of 23 mm at the apical inferior region of the left ventricle and a total late gadolinium enhancement (LGE) volume of <5%. (B and D) Follow-up CMR 3 years later showed progression of hypertrophy with a maximum wall thickness of 28 mm and (E) a total LGE volume of 15%.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. O‘Mahony C., Jichi F., Pavlou M., et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) Eur Heart J. 2014;35(30):2010–2020. - PubMed
    1. Ommen S.R., Mital S., Burke M.A., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159–240. - PubMed
    1. Schneider A.E., Burkhart H.M., Ackerman M.J., Dearani J.A., Wackel P., Cannon B.C. Minimally invasive epicardial implantable cardioverter-defibrillator placement for infants and children: an effective alternative to the transvenous approach. Heart Rhythm. 2016;13(9):1905–1912. - PubMed
    1. Levine B.D., Stray-Gundersen J. The medical care of competitive athletes: the role of the physician and individual assumption of risk. Med Sci Sports Exerc. 1994;26(10):1190–1192. - PubMed
    1. Baggish A.L., Ackerman M.J., Lampert R. Competitive sport participation among athletes with heart disease: a call for a paradigm shift in decision making. Circulation. 2017;136(17):1569–1571. - PubMed

Publication types

LinkOut - more resources